STAAR Surgical (NASDAQ:STAA) Receives Consensus Rating of “Hold” from Analysts

STAAR Surgical (NASDAQ:STAA) has been assigned an average rating of “Hold” from the ten research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $26.86.

STAA has been the topic of a number of research analyst reports. Piper Sandler reduced their target price on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 12th. Stifel Nicolaus reduced their target price on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. BTIG Research cut STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Finally, StockNews.com cut STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 23,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were acquired at an average cost of $24.33 per share, with a total value of $559,590.00. Following the completion of the transaction, the insider now owns 10,848,631 shares in the company, valued at $263,947,192.23. The trade was a 0.21 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased 402,024 shares of company stock valued at $6,936,904 over the last three months. 1.00% of the stock is owned by company insiders.

Institutional Trading of STAAR Surgical

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its position in shares of STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after acquiring an additional 31,212 shares during the last quarter. HighTower Advisors LLC purchased a new stake in shares of STAAR Surgical during the third quarter worth about $336,000. Polar Asset Management Partners Inc. increased its position in shares of STAAR Surgical by 44.3% during the third quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock worth $6,271,000 after acquiring an additional 51,800 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of STAAR Surgical by 411.7% during the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after acquiring an additional 172,779 shares during the last quarter. Finally, Defender Capital LLC. increased its position in shares of STAAR Surgical by 3.5% during the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock worth $17,041,000 after acquiring an additional 23,950 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Down 1.1 %

STAA stock opened at $17.50 on Tuesday. STAAR Surgical has a 52-week low of $13.50 and a 52-week high of $52.68. The stock has a market capitalization of $863.19 million, a price-to-earnings ratio of -42.68 and a beta of 0.62. The stock’s fifty day simple moving average is $21.70 and its 200-day simple moving average is $27.38.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.